Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Entinostat + Interleukin-12 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Entinostat | HDAC inhibitor SNDX-275|MS 275 | HDAC Inhibitor 45 | Entinostat (MS-275) inhibits HDAC activity, with selectivity towards HDAC1, 2, and 3, which results in increased histone acetylation, and potentially leads to decreased tumor cell proliferation and tumor growth (PMID: 19724929, PMID: 17383217, PMID: 32503469). | |
Interleukin-12 | Ro 24-7472|NM-IL-12|Edodekin alfa | Interleukin-12 (NM-IL-12) is a recombinant version of Interleukin-12 (IL-12), which may decrease tumor angiogenesis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03501381 | Phase II | Entinostat + Interleukin-12 Interleukin-12 | High Dose IL 2 and Entinostat in RCC | Active, not recruiting | USA | 0 |